Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of selective pulmonary artery perfusion with carboplatin in non-small cell lung cancer
NL-OMON32894Phase 1Not yet recruiting
- Sponsor
- cardioth chir
- Start
- Nov 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of carboplatin in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by cardioth chir. Primary endpoint: Toxicity. Planned start Nov 2008; status: not yet recruiting.
02
Drugs
carboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON32894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32894.